There are limited treatment options for patients with advanced/metastatic, triple-negative breast cancer because commonly used treatments in other breast cancer segments (i.e., hormonal therapies and HER2-targeted therapies) are ineffective in this disease subset. Hence, a high unmet need exists for efficacious targeted therapies for this patient population. Several novel therapies are in development for advanced/metastatic, triple-negative breast cancer; however, historically, it has been difficult for agents to improve outcomes for this hard-to-treat population. Our content examines key drivers of prescribing in this indication and analyses of significant commercial opportunities.

Related Reports

Breast Cancer - Landscape & Forecast - Disease Landscape & Forecast

The breast cancer market is rapidly evolving and presents new commercial opportunities for drug developers. CDK4/6 inhibitors (Pfizer’s Ibrance,...

View Details

Breast Cancer - Geographic Focus - China - Breast Cancer | China In-Depth | China

Breast cancer is the most commonly diagnosed cancer among Chinese women. A high incidence and a prolonged treatment duration make the treatment of breast cancer a lucrative commercial opportunity f...

View Details

Breast Cancer - Current Treatment - Detailed, Expanded Analysis (US)

Hormone receptor (HR)-positive / HER2-negative breast cancer is the most prevalent breast cancer subtype. Treatment decisions are influenced by disease stage, genetic test score, menopausal status,...

View Details

Breast Cancer - Current Treatment - Detailed, Expanded Analysis: Treatment Sequencing (US)

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into...

View Details